Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?

Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and typically arises in the context of chronic liver disease. With the increasing prevalence of metabolic disorders, metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver...

Full description

Saved in:
Bibliographic Details
Main Authors: Giuseppina Vizioli, Alberto Nicoletti, Daniela Feliciani, Barbara Funaro, Lorenzo Zileri Dal Verme, Francesca Romana Ponziani, Maria Assunta Zocco, Antonio Gasbarrini, Maurizio Gabrielli
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Applied Sciences
Subjects:
hepatocellular carcinoma (HCC)
metabolic-dysfunction-associated steatotic liver disease (MASLD)
liver
immunotherapy
Online Access:https://www.mdpi.com/2076-3417/15/5/2279
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-3417/15/5/2279

Similar Items